Clinical trials: Cancer in the Lung
Extensive-stage Small Cell Lung Cancer
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.
- Trial name
- LUMINANCE (NCT04774380)
- Testing
- Durvalumab, Cisplatin, Carboplatin
- Where
- 35 sites in Bulgaria, Canada and 4 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer Metastatic
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
The main purpose of this study is to evaluate the safety and activity of the study drug known as LY3023414 in combination with necitumumab in participants with metastatic squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT02443337
- Testing
- LY3023414, Necitumumab
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Non-squamous, Non-Small Cell Lung Cancer
The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
Non-interventional, multi-country, multi-centre cohort study based on existing data from medical records (paper or electronic) or electronic health records of patients with advanced NSCLC harbouring EGFR mutations and treated…
- Trial name
- UpSwinG (NCT04179890)
- Testing
- Afatinib (Gi(l)otrif®), Erlotinib (Tarceva®), Gefitinib (IRESSA®)
- Where
- United Kingdom
- Volunteers
- 462 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Cancer, Liver Cancer
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
This is a phase Ib open label, expansion study of CUDC-101 in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer tumors.
- Conditions
- Head and Neck Cancer, Liver Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT01171924
- Testing
- CUDC-101
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Curis, Inc.
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Non-small Cell Lung Cancer
Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
The purpose of this study is to determine whether it is safe to treat lung cancer patients who have undergone an attempt at curative resection with the combination of docetaxel and carboplatin.
- Trial name
- NCT00883675
- Testing
- Docetaxel-Carboplatin
- Where
- 12 sites in United States, China
- Volunteers
- 133 people
- Sponsor
- Michael Mann
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
Survival Prolongation by Rationale Innovative Genomics
Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) translocation, ROS1 mutation if…
- Trial name
- SPRING (NCT03386929)
- Testing
- Avelumab, Axitinib, Palbociclib
- Where
- 5 sites in United States, Israel and 2 more
- Volunteers
- 15 people
- Sponsor
- Worldwide Innovative Network Association
Ovarian Cancer, Non Small Cell Lung Cancer
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to estimate the rate of response for patients with ovarian, non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who are administered LY2523355.
- Conditions
- Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT01059643
- Testing
- LY2523355, pegfilgrastim
- Where
- 18 sites in United States
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
- Trial name
- NCT02695290
- Testing
- Afatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer, Pancreatic Cancer
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite
- Trial name
- PROACC-1 (NCT05546476)
- Testing
- ponsegromab
- Where
- 78 sites in United States, Australia and 9 more
- Volunteers
- 187 people
- Sponsor
- Pfizer
Lung Cancer
Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer
The purpose of this study is to find out what effects (good and/or bad) a tumor vaccine used in combination with two drugs (ATRA and cytoxan) have on the patient and their cancer.
- Trial name
- NCT00601796
- Testing
- Vaccine Treatment, Cyclophosphamide, All-trans retinoic acid (ATRA)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer
Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00798603
- Testing
- bevacizumab, carboplatin, pemetrexed disodium
- Where
- 217 sites in United States
- Volunteers
- 65 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer.
- Trial name
- NCT05242965
- Testing
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Non-Small Cell Lung Cancer (NSCLC)
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02521051
- Testing
- Alectinib, Bevacizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
This study will assess the prevalence of epidermal growth factor receptor (EGFR) mutations in newly diagnosed patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT01250119
- Testing
- erlotinib [Tarceva]
- Where
- 22 sites in United Kingdom
- Volunteers
- 688 people
- Sponsor
- Hoffmann-La Roche